Drug
pegylated interferon α-2b
pegylated interferon α-2b is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 33.3%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
1(20%)
Results Posted
100%(1 trials)
Terminated
2(40%)
Phase Distribution
Ph not_applicable
1
20%
Ph phase_2
4
80%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(1)
Terminated(2)
Other(1)
Detailed Status
Terminated2
Recruiting1
unknown1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (80.0%)
N/A1 (20.0%)
Trials by Status
recruiting120%
unknown120%
completed120%
terminated240%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_2
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
NCT05870475
unknownphase_2
Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
NCT04246359
terminatednot_applicable
Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
NCT00724061
terminatedphase_2
Nilotinib Plus Pegylated Interferon-α2b in CML
NCT01866553
completedphase_2
Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
NCT00623402
Clinical Trials (5)
Showing 5 of 5 trials
NCT05870475Phase 2
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
NCT04246359Phase 2
Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
NCT00724061Not Applicable
Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
NCT01866553Phase 2
Nilotinib Plus Pegylated Interferon-α2b in CML
NCT00623402Phase 2
Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5